For all patients with diabetes and established ASCVD or at very high risk for ASCVD, it is also reasonable to target a low-density lipoprotein (LDL) level < 70 mg / dL with maximally tolerated statin and addition of ezetimibe or a proprotein convertase subtilisin / kexin type 9 (PCSK - 9) inhibitor if necessary.